FDA Approves SPIRONOLACTONE — Zydus Lifesciences Limited

Zydus Lifesciences Limited received FDA approval for its generic version of Spirolactone, a potassium-sparing diuretic, likely introducing a new competitive option in the antihypertensive market. This addition to the portfolio could positively impact the company’s revenue streams while increasing market availability and pricing pressure for branded alternatives.